secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scholar Rock Holding Corp (SRRK)
CIK:        0001727196
Form:       8-K
Filed at:   2026-11-10T12:10:18+00:00
Accession:  0001193125-26-454423
Event type: m_and_a
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 2.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Scholar Rock to sell PRV to BioNTech for $205M; Q3 EPS loss $0.81, first ISEMBYLD revenue $0.6M
--------------------------------------------------------------------------------

- Definitive PRV asset purchase agreement signed Nov 9, 2026 with BioNTech US Inc.; $205M in cash payable at closing, subject to HSR waiting-period expiration.
- Q3 2026 net loss $107.2M ($0.81 per share) vs $102.2M ($0.90 per share) a year earlier; net product revenue of $0.6M from ISEMBYLD after Sept 11 FDA approval.
- Cash, cash equivalents and marketable securities of $413.6M at Sept 30, 2026; R&D $54.1M, SG&A $52.5M, stock-based compensation $17.9M.
- EMA validated the apitegromab MAA resubmission in October 2026, with CHMP opinion expected H1 2027; Japanese JNDA accepted under priority review (~9-month cycle).
- SRK-439 Phase 1 topline data expected by year-end 2026; FSHD FORGE Phase 2 enrolling ~60 patients; FDA granted Fast Track and Orphan Drug designations in September 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1727196/000119312526454423/0001193125-26-454423-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1727196/000119312526454423/srrk-20261110.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-454423

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer